Scop-induced dementia has been used extensively to assess potential therapeutic agents for treating AD.22 Scop is a nonselective muscarinic cholinergic receptor antagonist results in cholinergic dysfunction and consequently performance deficits in learning and memory.26 In particular, Scop impairs spatial learning and memory in MWM performance and is related to reductions in ACh and increased AChE activity in the hippocampus.27,28 Therefore, in this study, Scop was administered to induce AD. Here, ACHE is linked to dementia.